Volume 57, Issue 1, Pages (January 2010)

Slides:

Advertisements

Similar presentations

Volume 70, Issue 2, Pages (August 2016)

Advertisements

Volume 68, Issue 4, Pages (October 2015)

Volume 63, Issue 3, Pages (March 2013)

Volume 71, Issue 6, Pages (June 2017)

Volume 50, Issue 1, Pages (July 2006)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 58, Issue 2, Pages (August 2010)

Volume 44, Issue 6, Pages (December 2003)

Volume 58, Issue 4, Pages (October 2010)

Volume 70, Issue 1, Pages (July 2016)

Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer Marisa Warmuth,

Volume 59, Issue 3, Pages (March 2011)

Contemporary Management of the Painful Bladder: A Systematic Review

Volume 60, Issue 2, Pages (August 2011)

Volume 61, Issue 1, Pages (January 2012)

Maintenance Bacillus Calmette-Guérin: The Standard of Care for the Prophylaxis and Management of Intermediate- and High-Risk Non–Muscle-Invasive Bladder.

Volume 73, Issue 2, Pages (February 2018)

Volume 61, Issue 5, Pages (May 2012)

Control of Prostate Cancer by Transrectal HIFU in 227 Patients

Volume 69, Issue 1, Pages (January 2016)

Volume 71, Issue 6, Pages e171-e172 (June 2017)

Ashish M. Kamat, Sima Porten European Urology

Volume 73, Issue 5, Pages (May 2018)

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Prostate Cancer Epidemic in Sight?

Volume 63, Issue 1, Pages (January 2013)

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Volume 71, Issue 6, Pages (June 2017)

The Global Risk of Bladder Cancer: Let's Just Do Something About It!

Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer Sam Ladjevardi, Gabriel Sandblom,

What is New in Bladder Cancer Diagnosis and Management?

Nomograms for Bladder Cancer

New Trends in Bladder Cancer Management

Clinical Practice Recommendations for the Management of Non–Muscle Invasive Bladder Cancer Donald Lamm, Marc Colombel, Raj Persad, Mark Soloway, Andreas.

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 55, Issue 6, Pages (June 2009)

Volume 66, Issue 4, Pages (October 2014)

Volume 61, Issue 5, Pages (May 2012)

P.M.J. Moonen, L.A.L.M. Kiemeney, J.A. Witjes European Urology

Volume 61, Issue 6, Pages (June 2012)

Volume 69, Issue 3, Pages (March 2016)

Volume 70, Issue 1, Pages (July 2016)

Clinical Practice Recommendations for the Management of Non–Muscle Invasive Bladder Cancer Donald Lamm, Marc Colombel, Raj Persad, Mark Soloway, Andreas.

Prostate Cancer Epidemic in Sight?

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 53, Issue 6, Pages (June 2008)

Volume 66, Issue 2, Pages (August 2014)

Volume 63, Issue 3, Pages (March 2013)

Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review Sven van.

The Inside-Out Transobturator Male Sling for the Surgical Treatment of Stress Urinary Incontinence After Radical Prostatectomy: Midterm Results of a Single-Center.

Volume 70, Issue 2, Pages (August 2016)

Volume 53, Issue 1, Pages (January 2008)

Volume 68, Issue 4, Pages (October 2015)

Volume 50, Issue 5, Pages (November 2006)

Volume 50, Issue 3, Pages (September 2006)

Current Approaches to the Management of Non-Muscle Invasive Bladder Cancer: Comparison of Current Guidelines and Recommendations Raj Persad, Donald Lamm,

Testicular Cancer Variations in Time and Space in Europe

Volume 54, Issue 6, Pages (December 2008)

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Volume 53, Issue 5, Pages (May 2008)

Bladder Cancer: Highlights from 2006

European Urology is “Your” Journal

Volume 52, Issue 4, Pages (October 2007)

Volume 52, Issue 1, Pages (July 2007)

Volume 67, Issue 4, Pages (April 2015)

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Volume 54, Issue 1, Pages (July 2008)

Volume 51, Issue 5, Pages (May 2007)

Maximilian Burger, Ashish M. Kamat, David McConkey

Morgan Rouprêt, Per-Uno Malmstrom, Peter Black

Presentation transcript:

Volume 57, Issue 1, Pages 25-31 (January 2010) Bacillus Calmette-Guérin Is Superior to a Combination of Epirubicin and Interferon-α2b in the Intravesical Treatment of Patients with Stage T1 Urinary Bladder Cancer. A Prospective, Randomized, Nordic Study Miloš Duchek, Robert Johansson, Staffan Jahnson, Oddvar Mestad, Pekka Hellström, Sverker Hellsten, Per-Uno Malmström European Urology Volume 57, Issue 1, Pages 25-31 (January 2010) DOI: 10.1016/j.eururo.2009.09.038 Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 1 Treatment and assessment schedule. TURB=Transurethral resection of the bladder*; R=randomisation; Pex=multiple biopsies; BCG=bacillus Calmette-Guérin; IFN=interferon-α2b; Epi=epirubicin. * If no tumour, TURB at primary location; second look refers to TURB at the primary tumour location plus mapping. European Urology 2010 57, 25-31DOI: (10.1016/j.eururo.2009.09.038) Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 2 Flow of patients. BCG=bacillus Calmette-Guérin; Epi=epirubicin; IFN=interferon-α2b. European Urology 2010 57, 25-31DOI: (10.1016/j.eururo.2009.09.038) Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 3 Disease-free survival of patients according to randomisation arm (p=0.01). DFS=disease-free survival; BCG=bacillus Calmette-Guérin. European Urology 2010 57, 25-31DOI: (10.1016/j.eururo.2009.09.038) Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 4 Progression-free survival of patients according to randomisation arm. DFS=disease-free survival; BCG=bacillus Calmette-Guérin. European Urology 2010 57, 25-31DOI: (10.1016/j.eururo.2009.09.038) Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 5 Disease-free survival in subgroups according to (a) Tis (p<0.001), (b) grade 2 (p=0.09), and (c) grade 3 (p=0.055) status. DFS=disease-free survival; BCG=bacillus Calmette-Guérin; CIS=carcinoma in situ; Epi=epirubicin; IFN=interferon-α2b. European Urology 2010 57, 25-31DOI: (10.1016/j.eururo.2009.09.038) Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 6 Frequency of patients (%) with subjective urinary problems during treatment months. BCG=bacillus Calmette-Guérin; Epi=epirubicin; IFN=interferon-α2b. European Urology 2010 57, 25-31DOI: (10.1016/j.eururo.2009.09.038) Copyright © 2009 European Association of Urology Terms and Conditions